Fibroblast Activation Protein Inhibitor Theranostics: A Huge Opportunity with its Fair Share of Oncological Pitfalls

Akram Al-Ibraheem

doi:10.1055/s-0044-1787886

World Journal of Nuclear Medicine, Table of Contents

CC BY 4.0 · World J Nucl Med 2024; 23(02): 071-072
DOI: 10.1055/s-0044-1787886

Editorial

Fibroblast Activation Protein Inhibitor Theranostics: A Huge Opportunity with its Fair Share of Oncological Pitfalls

Authors

Akram Al-Ibraheem

¹Department of Nuclear Medicine, King Hussein Cancer Center (KHCC), Amman, Jordan

²Division of Nuclear Medicine, Department of Radiology and Nuclear Medicine, University of Jordan, Amman, Jordan

³Arab Society of Nuclear Medicine (ARSNM), Amman, Jordan

Abstract

Full Text

References

References
1 Pijl JP, Nienhuis PH, Kwee TC, Glaudemans AWJM, Slart RHJA, Gormsen LC. Limitations and pitfalls of FDG-PET/CT in infection and inflammation. Semin Nucl Med 2021; 51 (06) 633-645
2 Sung H, Ferlay J, Siegel RL. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
3 Mao X, Xu J, Wang W. et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer 2021; 20 (01) 131
4 Hicks RJ, Roselt PJ, Kallur KG, Tothill RW, Mileshkin L. FAPI PET/CT: will it end the hegemony of 18F-FDG in oncology?. J Nucl Med 2021; 62 (03) 296-302
5 Qin C, Song Y, Cai W, Lan X. Dimeric FAPI with potential for tumor theranostics. Am J Nucl Med Mol Imaging 2021; 11 (06) 537-541
6 Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023; 73 (01) 17-48
7 Al-Ibraheem A, Al-Qasem S, El Khaldi M, Amarin R. 68 Ga-FAPI PET/CT provides a clear picture of a Klatskin tumor that 18 F-FDG PET/CT missed. Clin Nucl Med 2023; 48 (06) e313-e315
8 Mori Y, Dendl K, Cardinale J, Kratochwil C, Giesel FL, Haberkorn U. FAPI PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease. Radiology 2023; 306 (02) e220749
9 Al-Ibraheem A, Alyasjeen SF, Abdlkadir AS, Sheikha AA. [⁶⁸Ga]Ga-DOTA-FAPI-04 PET/CT depicts metastases from medullary thyroid cancer that [⁶⁸Ga]Ga-DOTATOC PET/CT missed. Eur J Nucl Med Mol Imaging 2023; 50 (13) 4112-4113
10 Al-Ibraheem A, Zimmermann R, Abdlkadir AS, Herrmann K. Radiotheranostics Global Market and Future Developments. Elsevier; 2024
11 Al-Ibraheem A, Abdlkadir AS, Alalawi H, Badarneh M. 68Ga-FAPI PET/CT imaging: unveiling the hidden pitfalls. Clin Nucl Med 2023; 48 (11) 965-966
12 Bentestuen M, Al-Obaydi N, Zacho HD. FAPI-avid nonmalignant PET/CT findings: an expedited systematic review. Semin Nucl Med 2023; 53 (05) 694-705
13 Kessler L, Ferdinandus J, Hirmas N. et al. Pitfalls and common findings in 68Ga-FAPI PET: a pictorial analysis. J Nucl Med 2022; 63 (06) 890-896
14 Treglia G, Albano D. FAPI PET/CT in infectious, inflammatory, and rheumatological diseases: “watch it like a hawk” or “one swallow does not make a summer”?. Eur J Nucl Med Mol Imaging 2023; 50 (07) 1848-1850
15 Al-Ibraheem A, Badarneh M, Abdlkadir AS, Al-Qasem S, Ruzzeh S, Giammarile F. Investigating the diffuse pancreatic expression of [68Ga] Ga-DOTA-FAPI: location, timing, and molecular imaging approaches. Clin Transl Imaging 2024; (e-pub ahead of print).